Brian Monize
Endocrinology, Diabetes & Metabolism · Fort Lauderdale, FLNPI 1144596057
Payments from drug & device makers
Across 260 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$699
- AbbVie$565
- Boehringer Ingelheim$398
- Lilly USA, LLC$297
- AstraZeneca$287
- Amgen$216
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,39199%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 38 | $699 |
| AbbVie | 36 | $565 |
| Boehringer Ingelheim | 24 | $398 |
| Lilly USA, LLC | 20 | $297 |
| AstraZeneca | 15 | $287 |
| Amgen | 13 | $216 |
| Johnson & Johnson | 18 | $214 |
| Amarin Pharma, Inc. | 13 | $190 |
| Insulet Corporation | 7 | $184 |
| Valeritas, Inc. | 5 | $172 |
| Amneal Pharmaceuticals LLC | 8 | $140 |
| Mannkind Corporation | 8 | $122 |
| Novo Nordisk | 7 | $122 |
| BD | 7 | $118 |
| IBSA Pharma Inc. | 8 | $112 |
| Xeris Pharmaceuticals, Inc. | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 5 | $82 |
| Shire North American Group Inc | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Lifescan, Inc. | 3 | $56 |
| Corcept Therapeutics | 3 | $53 |
| Radius Health, Inc. | 3 | $50 |
| Abbott | 2 | $37 |
| Zealand Pharma US, Inc. | 2 | $29 |
| CSL Behring | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-GO$117
How this compares
$4,417 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 29 | $30,342 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $13,537 |
| Levothyroxine Sodium | 21 | $164 |
| Pioglitazone Hcl | 12 | $157 |
| Metformin Hcl | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy Xr | $398 | $43,87940 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $140 | $16421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Fort Lauderdale
- Ihosvani MiguelFort Lauderdale$701K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.